An agenda for "Collaborating to Advance Health Equity and Diabetes and Chronic Kidney Disease" is provided below for the convenience of conference attendees.

The conference is scheduled for Wednesday, February 10, 2021. It is an online event, with presentations scheduled for 10 a.m. - 3:05 p.m.

Downloadable Conference Materials:

Conference Agenda:

Opening Session
10 - 10:05 a.m. Opening Remarks
RADM Richardae Araojo, PharmD, MS (FDA Associate Commissioner for Minority Health)
10:05 - 10:15 a.m. Keynote Speaker
La Shawn McIver, MD, MPH (Director, CMS Office of Minority Health)
Session 1
10:15 - 11:30 a.m. Using Patient Experience Data and Community/System Approach to Inform Care, Drug Development, and the Overall Research Agenda

Moderator: Chanel Whittaker, PharmD, BCPS, CGP, FASCP (Associate Professor, Department of Pharmacy Practice and Science, UMSOP)

  • Andrea Furia-Helms, MPH (Director of Patient Affairs, FDA)
  • Richard Knight, MBA (President, AAKD Board of Directors)
  • Anne Bullock, MD (Director, IHS Division of Diabetes Treatment and Prevention)
  • Rana Malek, MD (Clinical Associate Professor, UMSOM)
  • Patrick Gee, PhD (Kidney Health Initiative Patient Family Partnership Council Member
Purpose: Leverage patient experience data and community/system to inform care, drug development, and overall research agenda to improve patient outcomes and reduce health inequities for diverse communities with diabetes and chronic kidney disease (CKD).
11:30 a.m. - 12:30 p.m. Lunch Break
Session 2
12:30 - 1:45 p.m. Diversity in Clinical Trials in Diabetes and Chronic Kidney Disease (CKD)

Moderator: Christine Lee, PharmD, PhD (Strategic Research Engagement Lead, OMHHE)

  • Milena Lolic, MD, MS (Lead Medical Officer, FDA)
  • Rekha Kambhampati, MD, MHS (Physician, FDA)
  • Andreea Lungu, MD (Physician, FDA)
  • Jovonni Spinner, DrPH, MPH, CHES (Senior Public Health Advisor, FDA)
  • Teisha Harris, MBA, MHS (Deputy Director and Chief Operating Officer, YCCI and Associate Director for Clinical Research, Yale School of Medicine)
Purpose: Explore barriers to diversity in clinical trials for CKD and diabetes and describe strategies to improve clinical trial diversity.
1:45 - 2 p.m. Break
Session 3
2 - 3 p.m. RWD Research in Diabetes and Chronic Kidney Disease (CKD)

Moderator: Charmaine Rochester, PharmD, CDCES (CDE), BCACP (Professor, Department of Pharmacy Practice and Science, UMSOP)

  • Clydette Powell, MD, MPH, FAAP (Designated Federal Officer, National Clinical Care Commission)
  • Leonard Pogach, MD, MBA, FACP (National Program Director, Diabetes and Endocrinology, VA)
  • Qi Liu, PhD, MStat, FCP (Senior Science Advisor, FDA)
  • Jenna Norton, PhD, MPH (Associate Director; Division of Kidney, Urologic, and Hematologic Diseases; NIH)
Purpose: Utilization of real-world data to inform strategies and decision making on management of diabetes and CKD.
3 - 3:05 p.m. Closing Remarks